Antiphospholipid antibodies and haemostasis;Anticorps antiphospholipides et hémostase

Revue de Medecine Interne

Volumn 33, Issue 4, 2012, Pages 181-188

  Masliah Planchon, J ^a   Darnige, L ^a  

^a HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

Author keywords

Antiphospholipid antibodies; Antiphospholipid syndrome; Hemostasis; Thrombosis

Indexed keywords

PHOSPHOLIPID ANTIBODY;

HEMOSTASIS; HUMAN; LABORATORY DIAGNOSIS; RISK ASSESSMENT; SHORT SURVEY; THROMBOSIS;

ANTIBODIES, ANTIPHOSPHOLIPID; ANTIPHOSPHOLIPID SYNDROME; BIOLOGICAL MARKERS; FEMALE; HEMOSTASIS; HUMANS; IMMUNOLOGIC FACTORS; PREDICTIVE VALUE OF TESTS; PREGNANCY; PREGNANCY COMPLICATIONS, HEMATOLOGIC; RISK ASSESSMENT; RISK FACTORS; SENSITIVITY AND SPECIFICITY; VENOUS THROMBOSIS;

EID: 84858750617     PISSN: 02488663     EISSN: 17683122     Source Type: Journal    
DOI: 10.1016/j.revmed.2011.10.008     Document Type: Short Survey

References (52)

1. Agar C., van Os G.M., Mörgelin M., Sprenger R.R., Marquart J.A., Urbanus R.T., et al. Beta 2-glycoprotein I can exist in two conformations: implications for our understanding of the antiphospholipid syndrome. Blood 2010, 116:1336-1343.
2. Bancsi L.F., van der Linden I.K., Bertina R.M. Beta 2-glycoprotein I deficiency and the risk of thrombosis. Thromb Haemost 1992, 67:649-653.
3. Cariou R., Tobelem G., Bellucci S., Soria J., Soria C., Maclouf J., et al. Effect of lupus anticoagulant on antithrombogenic properties of endothelial cells - inhibition of thrombomodulin-dependent protein C activation. Thromb Haemost 1988, 60:54-58.
4. Marciniak E., Romond E.H. Impaired catalytic function of activated protein C: a new in vitro manifestation of lupus anticoagulant. Blood 1989, 74:2426-2432.
5. Regnault V., Beguin S., Wahl D., de Maistre E., Coenraad Hemker H., Lecompte T. Thrombinography shows acquired resistance to activated protein C in patients with lupus anticoagulants. Thromb Haemost 2003, 89:208-212.
6. Merrill J.T., Zhang H.W., Shen C., Butman B.T., Jeffries E.P., Lahita R.G., et al. Enhancement of protein S anticoagulant function by beta 2-glycoprotein I, a major target antigen of antiphospholipid antibodies: beta 2-glycoprotein I interferes with binding of protein S to its plasma inhibitor, C4b-binding protein. Thromb Haemost 1999, 81:748-757.
7. Hurtado V., Montes R., Gris J.C., Bertolaccini M.L., Alonso A., Martinez-Gonzalez M.A., et al. Autoantibodies against EPCR are found in antiphospholipid syndrome and are a risk factor for fetal death. Blood 2004, 104:1369-1374.
8. Andree H.A., Stuart M.C., Hermens W.T., Reutelingsperger C.P., Hemker H.C., Frederik P.M., et al. Clustering of lipid-bound annexin V may explain its anticoagulant effect. J Biol Chem 1992, 267:17907-17912.
9. de Laat B., Wu X.X., van Lummel M., Derksen R.H., de Groot P.G., Rand J.H. Correlation between antiphospholipid antibodies that recognize domain I of beta 2-glycoprotein I and a reduction in the anticoagulant activity of annexin A5. Blood 2007, 109:1490-1494.
10. Rand J.H., Wu X.X., Andree H.A., Lockwood C.J., Guller S., Scher J., et al. Pregnancy loss in the antiphospholipid-antibody syndrome - a possible thrombogenic mechanism. N Engl J Med 1997, 337:154-160.
11. Rand J.H., Wu X.X., Quinn A.S., Chen P.P., Hathcock J.J., Taatjes D.J. Hydroxychloroquine directly reduces the binding of antiphospholipid antibody-beta 2-glycoprotein I complexes to phospholipid bilayers. Blood 2008, 112:1687-1695.
12. Rand J.H., Wu X.X., Quinn A.S., Ashton A.W., Chen P.P., Hathcock J.J., et al. Hydroxychloroquine protects the annexin A5 anticoagulant shield from disruption by antiphospholipid antibodies: evidence for a novel effect for an old antimalarial drug. Blood 2010, 115:2292-2299.
13. Szymezak J., Ankri A., Fischer A.M., Darnige L. Hydroxychloroquine : une nouvelle approche thérapeutique des manifestations thrombotiques du syndrome des antiphospholipides. Rev Med Interne 2010, 31:854-857.
14. Adams M.J., Donohoe S., Mackie I.J., Machin S.J. Anti-tissue factor pathway inhibitor activity in patients with primary antiphospholipid syndrome. Br J Haematol 2001, 114:375-379.
15. Forastiero R.R., Martinuzzo M.E., De Larrañaga G., Broze G.J. Antibodies to tissue factor pathway inhibitor are uncommonly detected in patients with infection-related antiphospholipid antibodies. J Thromb Haemost 2003, 1:2250-2251.
16. Salemink I., Blezer R., Willems G.M., Galli M., Bevers E., Lindhout T. Antibodies to beta 2-glycoprotein I associated with antiphospholipid syndrome suppress the inhibitory activity of tissue factor pathway inhibitor. Thromb Haemost 2000, 84:653-656.
17. Horbach D.A., van Oort E., Lisman T., Meijers J.C., Derksen R.H., de Groot P.G. Beta 2-glycoprotein I is proteolytically cleaved in vivo upon activation of fibrinolysis. Thromb Haemost 1999, 81:87-95.
18. Yang C.D., Hwang K.K., Yan W., Gallagher K., FitzGerald J., Grossman J.M., et al. Identification of anti-plasmin antibodies in the antiphospholipid syndrome that inhibit degradation of fibrin. J Immunol 2004, 172:5765-5773.
19. Cesarman-Maus G., Ríos-Luna N.P., Deora A.B., Huang B., Villa R., Cravioto Mdel C., et al. Autoantibodies against the fibrinolytic receptor, annexin 2, in antiphospholipid syndrome. Blood 2006, 107:4375-4382.
20. Cesarman-Maus G., Cantú-Brito C., Barinagarrementeria F., Villa R., Reyes E., Sanchez-Guerrero J., et al. Autoantibodies against the fibrinolytic receptor, annexin A2, in cerebral venous thrombosis. Stroke 2011, 42:501-503.
21. Cervera R., Piette J.C., Font J., Khamashta M.A., Shoenfeld Y., Camps M.T., et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1000 patients. Arthritis Rheum 2002, 46:1019-1027.
22. Godeau B., Piette J.C., Fromont P., Intrator L., Schaeffer A., Bierling P. Specific antiplatelet glycoprotein autoantibodies are associated with the thrombocytopenia of primary antiphospholipid syndrome. Br J Haematol 1997, 98:873-879.
23. Macchi L., Rispal P., Clofent-Sanchez G., Pellegrin J.L., Nurden P., Leng B., et al. Anti-platelet antibodies in patients with systemic lupus erythematosus and the primary antiphospholipid antibody syndrome: their relationship with the observed thrombocytopenia. Br J Haematol 1997, 98:336-341.
24. Moulis G, Delavigne K, Huguet F, Fortenfant F, Beyne-Rauzy O, Adoue D. Profil des anticorps antiphospholipides et risque de thrombose : étude comparative entre thrombopénie immunologique chronique et syndrome des antiphospholipides primaire. Rev Med Interne doi:10.1016/j.revmed.2011.07.014.
25. Lutters B.C., Derksen R.H., Tekelenburg W.L., Lenting P.J., Arnout J., de Groot P.G. Dimers of beta 2-glycoprotein I increase platelet deposition to collagen via interaction with phospholipids and the apolipoprotein E receptor 2'. J Biol Chem 2003, 278:33831-33838.
26. Shi T., Giannakopoulos B., Yan X., Yu P., Berndt M.C., Andrews R.K., et al. Anti-beta 2-glycoprotein I antibodies in complex with beta 2-glycoprotein I can activate platelets in a dysregulated manner via glycoprotein Ib-IX-V. Arthritis Rheum 2006, 54:2558-2567.
27. Pennings M.T., Derksen R.H., van Lummel M., Adelmeijer J., VanHoorelbeke K., Urbanus R.T., et al. Platelet adhesion to dimeric beta-glycoprotein I under conditions of flow is mediated by at least two receptors: glycoprotein Ibalpha and apolipoprotein E receptor 2'. J Thromb Haemost 2007, 5:369-377.
28. Lellouche F., Martinuzzo M., Said P., Maclouf J., Carreras L.O. Imbalance of thromboxane/prostacyclin biosynthesis in patients with lupus anticoagulant. Blood 1991, 78:2894-2899.
29. Alpert D.R., Salmon J.E. False-positive tests for heparin-induced thrombocytopenia in patients with antiphospholipid syndrome and systemic lupus erythematosus: a rebuttal. J Thromb Haemost 2010, 8:1439-1441.
30. Bourhim M., Darnige L., Legallais C., Arvieux J., Cevallos R., Pouplard C., et al. Anti-beta2-glycoprotein I antibodies recognizing platelet factor 4-heparin complex in antiphospholipid syndrome in patient substantiated with mouse model. J Mol Recognit 2003, 16:125-130.
31. Sikara M.P., Routsias J.G., Samiotaki M., Panayotou G., Moutsopoulos H.M., Vlachoyiannopoulos P.G. Beta 2 glycoprotein I binds platelet factor 4 (PF4): implications for the pathogenesis of antiphospholipid syndrome. Blood 2010, 115:713-723.
32. Pierangeli S.S., Colden-Stanfield M., Liu X., Barker J.H., Anderson G.L., Harris E.N. Antiphospholipid antibodies from antiphospholipid syndrome patients activate endothelial cells in vitro and in vivo. Circulation 1999, 99:1997-2002.
33. Reverter J.C., Tàssies D., Font J., Khamashta M.A., Ichikawa K., Cervera R., et al. Effects of human monoclonal anticardiolipin antibodies on platelet function and on tissue factor expression on monocytes. Arthritis Rheum 1998, 41:1420-1427.
34. Simantov R., LaSala J.M., Lo S.K., Gharavi A.E., Sammaritano L.R., Salmon J.E., et al. Activation of cultured vascular endothelial cells by antiphospholipid antibodies. J Clin Invest 1995, 96:2211-2219.
35. Romay-Penabad Z., Montiel-Manzano M.G., Shilagard T., Papalardo E., Vargas G., Deora A.B., et al. Annexin A2 is involved in antiphospholipid antibody-mediated pathogenic effects in vitro and in vivo. Blood 2009, 114:3074-3083.
36. Pierangeli S.S., Vega-Ostertag M.E., Raschi E., Liu X., Romay-Penabad Z., De Micheli V., et al. Toll-like receptor and antiphospholipid mediated thrombosis: in vivo studies. Ann Rheum Dis 2007, 66:1327-1333.
37. Satta N., Kruithof E.K., Fickentscher C., Dunoyer-Geindre S., Boehlen F., Reber G., et al. Toll-like receptor 2 mediates the activation of human monocytes and endothelial cells by antiphospholipid antibodies. Blood 2011, 117(20):5523-5531.
38. Raschi E., Testoni C., Bosisio D., Borghi M.O., Koike T., Mantovani A., et al. Role of the MyD88 transduction signaling pathway in endothelial activation by antiphospholipid antibodies. Blood 2003, 101:3495-3500.
39. Vega-Ostertag M., Casper K., Swerlick R., Ferrara D., Harris E.N., Pierangeli S.S. Involvement of p38 MAPK in the up-regulation of tissue factor on endothelial cells by antiphospholipid antibodies. Arthritis Rheum 2005, 52:1545-1554.
40. Ramesh S., Morrell C.N., Tarango C., Thomas G.D., Yuhanna I.S., Girardi G., et al. Antiphospholipid antibodies promote leukocyte-endothelial cell adhesion and thrombosis in mice by antagonizing eNOS via β2GPI and apoER2. J Clin Invest 2011, 121:120-211.
41. Cuadrado M.J., López-Pedrera C., Khamashta M.A., Camps M.T., Tinahones F., Torres A., et al. Thrombosis in primary antiphospholipid syndrome: a pivotal role for monocyte tissue factor expression. Arthritis Rheum 1997, 40:834-841.
42. Sorice M., Longo A., Capozzi A., Garofalo T., Misasi R., Alessandri C., et al. Anti-beta 2-glycoprotein I antibodies induce monocyte release of tumor necrosis factor alpha and tissue factor by signal transduction pathways involving lipid rafts. Arthritis Rheum 2007, 56:2687-2697.
43. Miyakis S., Lockshin M.D., Atsumi T., Branch D.W., Brey R.L., Cervera R., et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006, 4:295-306.
44. Pengo V., Tripodi A., Reber G., Rand J.H., Ortel T.L., Galli M., et al. Update of the guidelines for lupus anticoagulant detection. Subcommittee on lupus anticoagulant/antiphospholipid antibody of the scientific and standardisation Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost 2009, 7:1737-1740.
45. Pengo V., Biasiolo A., Pegoraro C., Cucchini U., Noventa F., Iliceto S. Antibody profiles for the diagnosis of antiphospholipid syndrome. Thromb Haemost 2005, 93:1147-1152.
46. Robert A., Le Querrec A., Delahousse B., Caron C., Houbouyan L., Boutière B., et al. Control of oral anticoagulation in patients with the antiphospholipid syndrome - influence of the lupus anticoagulant on International Normalized Ratio. Thromb Haemost 1998, 80:99-103.
47. Simmelink M.J., Derksen R.H., Arnout J., De Groot P.G. A simple method to discriminate between beta 2-glycoprotein I- and prothrombin-dependent lupus anticoagulants. J Thromb Haemost 2003, 1:740-747.
48. de Laat H.B., Derksen R.H., Urbanus R.T., Roest M., de Groot P.G. Beta 2-glycoprotein I-dependent lupus anticoagulant highly correlates with thrombosis in the antiphospholipid syndrome. Blood 2004, 104:3598-3602.
49. de Laat B., Derksen R.H., Reber G., Musial J., Swadzba J., Bozic B., et al. An international multicentre-laboratory evaluation of a new assay to detect specifically lupus anticoagulants dependent on the presence of anti-beta 2-glycoprotein autoantibodies. J Thromb Haemost 2011, 9:149-153.
50. de Laat B., Derksen R.H., Urbanus R.T., de Groot P.G. IgG antibodies that recognize epitope Gly40-Arg43 in domain I of beta 2-glycoprotein I cause LAC, and their presence correlates strongly with thrombosis. Blood 2005, 105:1540-1545.
51. de Laat B., Pengo V., Pabinger I., Musial J., Voskuyl A.E., Bultink I.E., et al. The association between circulating antibodies against domain I of beta 2-glycoprotein I and thrombosis: an international multicenter study. J Thromb Haemost 2009, 7:1767-1773.
52. Rand J.H., Wu X.X., Lapinski R., van Heerde W.L., Reutelingsperger C.P., Chen P.P., et al. Detection of antibody-mediated reduction of annexin A5 anticoagulant activity in plasmas of patients with the antiphospholipid syndrome. Blood 2004, 104:2783-2790.